Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Notes underwriting agrmnt
Inv. presentation
Quarterly results
Appointed COO
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update"
05/15/2023 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update"
11/14/2022 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update"
08/15/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/28/2022 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update"
01/28/2022 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update",
"Transcript of Conference Call by the Company on November 15, 2021, furnished hereto"
08/05/2021 8-K Quarterly results
Docs: "BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update"
04/26/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
10/15/2020 8-K Quarterly results
08/11/2016 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update"
05/10/2016 8-K Form 8-K - Current report
08/13/2015 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update"
05/14/2015 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Announces First Quarter 2015 Financial Results and Provides Corporate Update"
11/13/2014 8-K Quarterly results
Docs: "BrainStorm Announces Financial Results for the Third Quarter of 2014 and Provides Corporate Update Conference call today at 8.30 AM EST NEW YORK, PETACH TIKVAH – November 13, 2014 - BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three and nine months ending September 30, 2014. Tony Fiorino, MD, PhD, Chief Executive Officer of BrainStorm, commented, “The third quarter was extremely productive from a clinical as well as operational perspective. We added a second site to our phase 2 ALS study and received FDA clearance for manufacturing at our third site, and enrollment has moved along as planned. Also in the quarter, the FDA granted Fast Track designation to NurOwn™ in ALS..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy